Log in

ASX:RAP - Resapp Health Stock Price, Forecast & News

+0.01 (+4.08 %)
(As of 02/16/2020 04:00 PM ET)
Today's Range
Now: A$0.26
50-Day Range
MA: A$0.26
52-Week Range
Now: A$0.26
Volume1.34 million shs
Average VolumeN/A
Market Capitalization$177.55 million
P/E RatioN/A
Dividend YieldN/A
ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company delivers mobile software apps in various clinical settings, including telehealth, emergency, urgent care, and primary care. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was founded in 2014 and is headquartered in Brisbane, Australia.

Industry, Sector and Symbol

Industry Health Information Services
Phone61 7 3724 0035



Sales & Book Value

Annual Sales$2.83 million
Cash FlowA$0.01 per share
Book ValueA$0.01 per share



Market Cap$177.55 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RAP News and Ratings via Email

Sign-up to receive the latest news and ratings for RAP and its competitors with MarketBeat's FREE daily newsletter.

Resapp Health (ASX:RAP) Frequently Asked Questions

What is Resapp Health's stock symbol?

Resapp Health trades on the ASX under the ticker symbol "RAP."

Has Resapp Health been receiving favorable news coverage?

News headlines about RAP stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Resapp Health earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Resapp Health.

Who are some of Resapp Health's key competitors?

Who are Resapp Health's key executives?

Resapp Health's management team includes the folowing people:
  • Dr. Anthony Keating, CEO, MD & Director
  • Ms. Kay Taylor Ph.D., VP of Strategic Devel. & Operations
  • Dr. Udantha Abeyratne, Chief Scientist & Scientific Advisor
  • Ms. Nicki Farley, Company Sec. (Age 43)
  • Dr. Clas Källander, Founder and Director of R&D of Cavidi AB

What is Resapp Health's stock price today?

One share of RAP stock can currently be purchased for approximately A$0.26.

How big of a company is Resapp Health?

Resapp Health has a market capitalization of $177.55 million and generates $2.83 million in revenue each year. View Additional Information About Resapp Health.

What is Resapp Health's official website?

The official website for Resapp Health is http://www.resapphealth.com.au/.

How can I contact Resapp Health?

The company can be reached via phone at 61 7 3724 0035.

MarketBeat Community Rating for Resapp Health (ASX RAP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  4
MarketBeat's community ratings are surveys of what our community members think about Resapp Health and other stocks. Vote "Outperform" if you believe RAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel